ABSTRACT
Cyclobutane rings are important in medicinal chemistry, yet few enantioselective methods exist to access this scaffold. In particular, cyclobutylboronates are receiving increasing attention in the literature due to the synthetic versatility of alkylboronic esters and the increasing role of boronic acids in drug discovery. Herein, a conjugate borylation of α-alkyl,ß-aryl/alkyl cyclobutenones is reported leading to the first synthesis of enantioenriched tertiary cyclobutylboronates. Cyclobutanones with two stereogenic centers are obtained in good to high yield, with high enantioselectivity and diastereoselectivity. Vital to this advance are the development of a novel approach to α,ß unsymmetrically disubstituted cyclobutenone substrates and the use of a high-throughput chiral ligand screening platform. The synthetic utility of both the boronic ester and ketone functionalities is displayed, with remarkable chemoselectivity for either group being possible in this small ring scaffold.
ABSTRACT
The discovery of D1 subtype-selective agonists with drug-like properties has been an enduring challenge for the greater part of 40 years. All known D1-selective agonists are catecholamines that bring about receptor desensitization and undergo rapid metabolism, thus limiting their utility as a therapeutic for chronic illness such as schizophrenia and Parkinson's disease. Our high-throughput screening efforts on D1 yielded a single non-catecholamine hit PF-4211 (6) that was developed into a series of potent D1 receptor agonist leads with high oral bioavailability and CNS penetration. An important structural feature of this series is the locked biaryl ring system resulting in atropisomerism. Disclosed herein is a summary of our hit-to-lead efforts on this series of D1 activators culminating in the discovery of atropisomer 31 (PF-06256142), a potent and selective orthosteric agonist of the D1 receptor that has reduced receptor desensitization relative to dopamine and other catechol-containing agonists.
Subject(s)
Dopamine Agonists/chemistry , Dopamine Agonists/pharmacology , Receptors, Dopamine D1/agonists , Animals , Biological Availability , CHO Cells , Cricetulus , Cyclic AMP/metabolism , Dogs , Dopamine Agonists/adverse effects , Dose-Response Relationship, Drug , HEK293 Cells , Half-Life , High-Throughput Screening Assays/methods , Humans , Madin Darby Canine Kidney Cells , Male , Mice, Inbred Strains , Neurons/drug effects , Neurons/metabolism , Rats , Receptors, Dopamine D1/metabolism , Stereoisomerism , Structure-Activity RelationshipABSTRACT
Herein, 3,5-bicyclic aryl piperidines are derivatized to generate chiral B/N FLPs. Initially, the twofold symmetric amine C6H2F2(C5H8NiPr) 1 was converted in a series of synthetic steps to the styrene-derivative C6HF2(C5H8NiPr)(CH[double bond, length as m-dash]CH2) 4. Efforts to hydroborate the vinyl fragment proved challenging as a result of the strongly basic nitrogen, although the species C6HF2(C5H8N(H)iPr)(CH2CH2B(OH)(C6F5)2) 5 was crystallographically characterized. Modification of the system was achieved by conversion of the amine C6H2F2(C5H8NH) 6 to C6HF2(C5H8NPh)(CH[double bond, length as m-dash]CH2) 9. Hydroboration of 9 with 9-BBN or HB(C6F5)2 gave C6HF2(C5H8NPh)(CH2CH2BBN) 10 or C6HF2(C5H8NPh)(CH2CH2B(C6F5)2) 11, respectively. The latter species was derivatized by complexation of PPh3 to give C6HF2(C5H8NPh)(CH2CH2B(C6F5)2)(PPh3) 12. The Lewis acidities of 10 and 11 were assessed by the Gutman-Beckett test and by computations of the FIA and GEI. While 10 did not effect HD scrambling or hydrogenation of N-phenylbenzylimine, 11 was effective in HD scrambling. Despite this, no reduction of N-t-butylbenzylimine or N-phenylbenzylimine was achieved. These data demonstrate that 10 lacks the threshold combination of Lewis acidity and basicity to activate H2, while 11 lacks the steric demands about boron to preclude classical Lewis acid-base bond formation with imine substrates.
ABSTRACT
Ongoing interest in the discovery of selective JAK3 inhibitors led us to design novel covalent inhibitors that engage the JAK3 residue Cys909 by cyanamide, a structurally and mechanistically differentiated electrophile from other cysteine reacting groups previously incorporated in JAK3 covalent inhibitors. Through crystallography, kinetic, and computational studies, interaction of cyanamide 12 with Cys909 was optimized leading to potent and selective JAK3 inhibitors as exemplified by 32. In relevant cell-based assays and in agreement with previous results from this group, 32 demonstrated that selective inhibition of JAK3 is sufficient to drive JAK1/JAK3-mediated cellular responses. The contribution from extrahepatic processes to the clearance of cyanamide-based covalent inhibitors was also characterized using metabolic and pharmacokinetic data for 12. This work also gave key insights into a productive approach to decrease glutathione/glutathione S-transferase-mediated clearance, a challenge typically encountered during the discovery of covalent kinase inhibitors.
Subject(s)
Cyanamide/chemistry , Cyanamide/pharmacology , Janus Kinase 3/antagonists & inhibitors , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/pharmacology , Animals , Cyanamide/pharmacokinetics , Drug Evaluation, Preclinical , Humans , Inhibitory Concentration 50 , Janus Kinase 3/chemistry , Male , Models, Molecular , Protein Conformation , Protein Kinase Inhibitors/pharmacokinetics , Rats , Tissue DistributionABSTRACT
Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that simultaneously bind to a target protein and an E3 ligase, thereby leading to ubiquitination and subsequent degradation of the target. They present an exciting opportunity to modulate proteins in a manner independent of enzymatic or signaling activity. As such, they have recently emerged as an attractive mechanism to explore previously "undruggable" targets. Despite this interest, fundamental questions remain regarding the parameters most critical for achieving potency and selectivity. Here we employ a series of biochemical and cellular techniques to investigate requirements for efficient knockdown of Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase essential for B cell maturation. Members of an 11-compound PROTAC library were investigated for their ability to form binary and ternary complexes with BTK and cereblon (CRBN, an E3 ligase component). Results were extended to measure effects on BTK-CRBN cooperative interactions as well as in vitro and in vivo BTK degradation. Our data show that alleviation of steric clashes between BTK and CRBN by modulating PROTAC linker length within this chemical series allows potent BTK degradation in the absence of thermodynamic cooperativity.
Subject(s)
Protein-Tyrosine Kinases/metabolism , Proteolysis , Ubiquitin-Protein Ligases/metabolism , Ubiquitination , Agammaglobulinaemia Tyrosine Kinase , Animals , Cells, Cultured , Ligands , Polyubiquitin/metabolism , Rats , ThermodynamicsABSTRACT
Many diseases are believed to be driven by pathological levels of reactive oxygen species (ROS) and oxidative stress has long been recognized as a driver for inflammatory disorders. Apoptosis signal-regulating kinase 1 (ASK1) has been reported to be activated by intracellular ROS and its inhibition leads to a down regulation of p38-and JNK-dependent signaling. Consequently, ASK1 inhibitors may have the potential to treat clinically important inflammatory pathologies including renal, pulmonary and liver diseases. Analysis of the ASK1 ATP-binding site suggested that Gln756, an amino acid that rarely occurs at the GK+2 position, offered opportunities for achieving kinase selectivity for ASK1 which was applied to the design of a parallel medicinal chemistry library that afforded inhibitors of ASK1 with nanomolar potency and excellent kinome selectivity. A focused optimization strategy utilizing structure-based design resulted in the identification of ASK1 inhibitors with low nanomolar potency in a cellular assay, high selectivity when tested against kinase and broad pharmacology screening panels, and attractive physicochemical properties. The compounds we describe are attractive tool compounds to inform the therapeutic potential of ASK1 inhibition.
Subject(s)
Amides/pharmacology , MAP Kinase Kinase Kinase 5/antagonists & inhibitors , Protein Kinase Inhibitors/pharmacology , Amides/chemical synthesis , Amides/chemistry , Cells, Cultured , Crystallography, X-Ray , Dose-Response Relationship, Drug , HEK293 Cells , Humans , MAP Kinase Kinase Kinase 5/metabolism , Models, Molecular , Molecular Structure , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/chemistry , Recombinant Proteins/metabolism , Structure-Activity RelationshipABSTRACT
Chemical probes are required for preclinical target validation to interrogate novel biological targets and pathways. Selective inhibitors of the CREB binding protein (CREBBP)/EP300 bromodomains are required to facilitate the elucidation of biology associated with these important epigenetic targets. Medicinal chemistry optimization that paid particular attention to physiochemical properties delivered chemical probes with desirable potency, selectivity, and permeability attributes. An important feature of the optimization process was the successful application of rational structure-based drug design to address bromodomain selectivity issues (particularly against the structurally related BRD4 protein).
Subject(s)
CREB-Binding Protein/antagonists & inhibitors , Drug Design , E1A-Associated p300 Protein/antagonists & inhibitors , Morpholines/pharmacology , CREB-Binding Protein/metabolism , Chemistry, Pharmaceutical , Dose-Response Relationship, Drug , E1A-Associated p300 Protein/metabolism , Humans , Molecular Structure , Morpholines/chemical synthesis , Morpholines/chemistry , Structure-Activity RelationshipABSTRACT
Significant work has been dedicated to the discovery of JAK kinase inhibitors resulting in several compounds entering clinical development and two FDA approved NMEs. However, despite significant effort during the past 2 decades, identification of highly selective JAK3 inhibitors has eluded the scientific community. A significant effort within our research organization has resulted in the identification of the first orally active JAK3 specific inhibitor, which achieves JAK isoform specificity through covalent interaction with a unique JAK3 residue Cys-909. The relatively rapid resynthesis rate of the JAK3 enzyme presented a unique challenge in the design of covalent inhibitors with appropriate pharmacodynamics properties coupled with limited unwanted off-target reactivity. This effort resulted in the identification of 11 (PF-06651600), a potent and low clearance compound with demonstrated in vivo efficacy. The favorable efficacy and safety profile of this JAK3-specific inhibitor 11 led to its evaluation in several human clinical studies.
Subject(s)
Janus Kinase 3/antagonists & inhibitors , Protein Kinase Inhibitors/chemistry , Pyrimidines/chemistry , Pyrroles/chemistry , Signal Transduction/drug effects , Administration, Oral , Drug Design , Humans , Janus Kinase 3/metabolism , Protein Kinase Inhibitors/administration & dosage , Protein Kinase Inhibitors/pharmacology , Pyrimidines/administration & dosage , Pyrimidines/pharmacology , Pyrroles/administration & dosage , Pyrroles/pharmacologyABSTRACT
By use of a structure-based computational method for identification of structurally novel Janus kinase (JAK) inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles was identified as selective pan-JAK inhibitors with a type 1.5 binding mode. Optimization of the series for potency and increased duration of action commensurate with inhaled or topical delivery resulted in potent pan-JAK inhibitor 2 (PF-06263276), which was advanced into clinical studies.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Heterocyclic Compounds, 2-Ring/pharmacology , Indazoles/pharmacology , Janus Kinases/antagonists & inhibitors , Lung Diseases/drug therapy , Protein Kinase Inhibitors/pharmacology , Skin Diseases/drug therapy , Administration, Cutaneous , Administration, Inhalation , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/chemical synthesis , Anti-Inflammatory Agents/toxicity , Binding Sites , Crystallography, X-Ray , Dogs , Drug Design , Hepatocytes/metabolism , Heterocyclic Compounds, 2-Ring/administration & dosage , Heterocyclic Compounds, 2-Ring/chemical synthesis , Heterocyclic Compounds, 2-Ring/toxicity , Humans , Indazoles/administration & dosage , Indazoles/chemical synthesis , Indazoles/toxicity , Janus Kinase 1/antagonists & inhibitors , Janus Kinase 2/antagonists & inhibitors , Janus Kinase 3/antagonists & inhibitors , Mice, Inbred BALB C , Microsomes, Liver/metabolism , Phosphorylation , Protein Kinase Inhibitors/administration & dosage , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/toxicity , Rats , SolubilityABSTRACT
Bromodomains are involved in transcriptional regulation through the recognition of acetyl lysine modifications on diverse proteins. Selective pharmacological modulators of bromodomains are lacking, although the largely hydrophobic nature of the pocket makes these modules attractive targets for small-molecule inhibitors. This work describes the structure-based design of a highly selective inhibitor of the CREB binding protein (CBP) bromodomain and its use in cell-based transcriptional profiling experiments. The inhibitor downregulated a number of inflammatory genes in macrophages that were not affected by a selective BET bromodomain inhibitor. In addition, the CBP bromodomain inhibitor modulated the mRNA level of the regulator of G-protein signaling 4 (RGS4) gene in neurons, suggesting a potential therapeutic opportunity for CBP inhibitors in the treatment of neurological disorders.
Subject(s)
CREB-Binding Protein/antagonists & inhibitors , Drug Design , Small Molecule Libraries/chemistry , CREB-Binding Protein/genetics , Fluorescence Resonance Energy Transfer , Gene Expression Regulation/drug effects , Humans , Protein Structure, Tertiary , RGS Proteins/genetics , Small Molecule Libraries/pharmacology , TranscriptomeABSTRACT
A versatile synthesis of 7-azaindoles from substituted 2-fluoropyridines is described. C3-metalation and 1,4-addition to nitroolefins provide substituted 2-fluoro-3-(2-nitroethyl)pyridines. A facile oxidative Nef reaction/reductive amination/intramolecular SNAr sequence furnishes 7-azaindolines. Finally, optional regioselective electrophilic C5-substitution (e.g., bromination or nitration) and subsequent in situ oxidation delivers highly functionalized 7-azaindoles in high overall efficiency.
ABSTRACT
New modes of chemical reactivity are of high value to synthetic organic chemistry. In this vein, carbon-carbon (C-C) activation is an emerging field that offers new possibilities for synthesizing valuable complex molecules. This review discusses the pioneering stoichiometric discoveries in this field up to the most recent synthetic applications that apply catalytic transformations. Specifically, the review focuses on C-C activation in relatively unstrained systems, including stoichiometric reactions, chelation-directed and chelation-free catalytic reactions. While the field of C-C activation of relatively unstrained systems is underdeveloped, we expect that this review will provide insight into new developments and pave the path for robust, practical applications.
ABSTRACT
Anti-nicotine vaccines may aid smoking cessation via the induction of anti-nicotine antibodies (Ab) which reduce nicotine entering the brain, and hence the associated reward. Ab function depends on both the quantity (titer) and the quality (affinity) of the Ab. Anti-nicotine vaccines tested previously in clinical studies had poor efficacy despite high Ab titer, and this may be due to inadequate function if Ab of low affinity were induced. In this study, we designed and synthesized a series of novel nicotine-like haptens which were all linked to diphtheria toxoid (DT) as carrier, but which differed in the site of attachment of linker to nicotine, the nature of linker used, and the handle used to attach the hapten to DT. The resulting hapten conjugates were evaluated in a mouse model, using CpG (a TLR9 agonist) and aluminum hydroxide (Al(OH)3) as adjuvants, whereby Ab titers, affinity and function were evaluated using a radiolabeled nicotine challenge model. A series of additional linkers varying in length, rigidity and polarity were used with a single hapten to generate additional DT-conjugates, which were also tested in mice. Conjugates made with different haptens resulted in various titers of anti-nicotine Ab. Several haptens gave similarly high Ab titers, but among these, Ab affinity and hence function varied considerably. Linker also influenced Ab titer, affinity and function. These results demonstrate that immune responses induced in mice by nicotine-conjugate antigens are greatly influenced by hapten design including site of attachment of linker to nicotine, the nature of linker used, and the handle used to attach the hapten to DT. While both Ab titer and affinity contributed to function, affinity was more sensitive to antigen differences.
Subject(s)
Antibodies/immunology , Antigens/immunology , Haptens/immunology , Nicotine/immunology , Smoking Prevention , Vaccines/immunology , Adjuvants, Immunologic/chemistry , Aluminum Hydroxide/chemistry , Animals , Antibodies/blood , Antibodies/chemistry , Antibody Affinity , Antibody Specificity , Antigens/chemistry , Diphtheria Toxoid/chemistry , Diphtheria Toxoid/immunology , Female , Haptens/chemistry , Humans , Immunoconjugates/chemistry , Mice , Mice, Inbred BALB C , Molecular Mimicry , Nicotine/chemistry , Oligodeoxyribonucleotides/chemistry , Oligodeoxyribonucleotides/immunology , Protein Engineering/methods , Smoking/immunology , Structure-Activity Relationship , Vaccines/administration & dosage , Vaccines/chemistryABSTRACT
(-)-Codeine 1 was converted into previously unknown 7ß-methyl-7,8-dihydrocodeine/morphine derivatives such as 13 via classical diaxial opening of α-epoxide 3. Several analogs exhibited dual µ/δ-agonist activity.
Subject(s)
Codeine/analogs & derivatives , Codeine/pharmacology , Receptors, Opioid, delta/agonists , Receptors, Opioid, mu/agonists , Animals , Epoxy Compounds/chemistry , Epoxy Compounds/pharmacology , Humans , Mice , Models, Molecular , Morphinans/chemistry , Morphinans/pharmacology , Receptors, Opioid, delta/metabolism , Receptors, Opioid, mu/metabolismABSTRACT
Previous studies have suggested that treatment with antagonists or partial agonists of nicotinic acetylcholine receptors containing the ß2-subunit (ß2 nAChRs) results in antidepressant-like effects. In this study, we tested three novel compounds with different affinity and functional efficacy at α4ß2 nAChRs, which were synthesized as part of nAChR discovery projects at Pfizer, in the tail-suspension, forced-swim, and novelty-suppressed feeding tests of antidepressant efficacy. All compounds tested reduced immobility in the forced-swim test and one of the compounds also reduced immobility in the tail-suspension test. All the compounds appeared to affect food intake on their own, with two compounds reducing feeding significantly in the home cage, precluding a clear interpretation of the results in the novelty-suppressed feeding test. None of the compounds altered locomotor activity at the doses and time points used here. Therefore, a subset of these compounds has pharmacological and behavioral properties that demonstrate the potential of nicotinic compounds as a treatment of mood disorders. Further development of nicotinic-based antidepressants should focus on increasing nAChR subtype selectivity to obtain consistent antidepressant properties with an acceptable side-effect profile.
Subject(s)
Antidepressive Agents , Nicotinic Agonists/pharmacology , Receptors, Nicotinic/drug effects , Animals , Environment , Feeding Behavior/drug effects , Hindlimb Suspension/psychology , Male , Mice , Mice, Inbred C57BL , Motor Activity/drug effects , Nicotine/pharmacology , Swimming/psychologyABSTRACT
Alcohol use disorders (AUDs) impact millions of individuals and there remain few effective treatment strategies. Despite evidence that neuronal nicotinic acetylcholine receptors (nAChRs) have a role in AUDs, it has not been established which subtypes of the nAChR are involved. Recent human genetic association studies have implicated the gene cluster CHRNA3-CHRNA5-CHRNB4 encoding the α3, α5, and ß4 subunits of the nAChR in susceptibility to develop nicotine and alcohol dependence; however, their role in ethanol-mediated behaviors is unknown due to the lack of suitable and selective research tools. To determine the role of the α3, and ß4 subunits of the nAChR in ethanol self-administration, we developed and characterized high-affinity partial agonists at α3ß4 nAChRs, CP-601932, and PF-4575180. Both CP-601932 and PF-4575180 selectively decrease ethanol but not sucrose consumption and operant self-administration following long-term exposure. We show that the functional potencies of CP-601932 and PF-4575180 at α3ß4 nAChRs correlate with their unbound rat brain concentrations, suggesting that the effects on ethanol self-administration are mediated via interaction with α3ß4 nAChRs. Also varenicline, an approved smoking cessation aid previously shown to decrease ethanol consumption and seeking in rats and mice, reduces ethanol intake at unbound brain concentrations that allow functional interactions with α3ß4 nAChRs. Furthermore, the selective α4ß2(*) nAChR antagonist, DHßE, did not reduce ethanol intake. Together, these data provide further support for the human genetic association studies, implicating CHRNA3 and CHRNB4 genes in ethanol-mediated behaviors. CP-601932 has been shown to be safe in humans and may represent a potential novel treatment for AUDs.
Subject(s)
Alcohol Drinking/drug therapy , Alcohol Drinking/psychology , Conditioning, Operant/drug effects , Nicotinic Agonists/therapeutic use , Acetylcholine/pharmacology , Animals , Azabicyclo Compounds/chemistry , Azabicyclo Compounds/pharmacology , Behavior, Animal/drug effects , Benzazepines/chemistry , Benzazepines/pharmacology , Brain/drug effects , Brain/metabolism , Cell Line, Transformed , Choice Behavior/drug effects , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Interactions , Ethanol/administration & dosage , Humans , Male , Nicotinic Agonists/chemistry , Nicotinic Agonists/pharmacology , Protein Binding/drug effects , Rats , Rats, Sprague-Dawley , Receptors, Nicotinic/genetics , Receptors, Nicotinic/metabolism , Self Administration/methods , Taste/drug effects , Time Factors , Transfection/methodsABSTRACT
We report the synthesis of a series of [3.2.1]azabicyclic biaryl ethers as selective agonists of alpha3- and alpha6-containing nicotinic receptors. In particular, compound 17a from this series is a potent alpha3beta4 and alpha6/4beta4 receptor agonist in terms of both binding and functional activity. Compound 17a also shows potent in vivo activity in CNS-mediated animal models that are sensitive to antipsychotic drugs. Compound 17a may thus be a useful tool for studying the role of alpha3beta4 and alpha6/4beta4 nicotinic receptors in CNS pharmacology.
Subject(s)
Azabicyclo Compounds/chemistry , Nicotinic Agonists/chemistry , Receptors, Nicotinic/chemistry , Sulfonamides/chemistry , Azabicyclo Compounds/chemical synthesis , Azabicyclo Compounds/pharmacology , Nicotinic Agonists/chemical synthesis , Nicotinic Agonists/pharmacology , Receptors, Nicotinic/metabolism , Structure-Activity Relationship , Sulfonamides/chemical synthesis , Sulfonamides/pharmacologyABSTRACT
A novel alpha 7 nAChR agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (24, CP-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and Alzheimer's disease. Compound 24 is a potent and selective compound with excellent pharmaceutical properties. In rodent, the compound displays high oral bioavailability and excellent brain penetration affording high levels of receptor occupancy and in vivo efficacy in auditory sensory gating and novel object recognition. The structural diversity of this compound and its preclinical in vitro and in vivo package support the hypothesis that alpha 7 nAChR agonists may have potential as a pharmacotherapy for the treatment of cognitive deficits in schizophrenia.
Subject(s)
Azabicyclo Compounds/chemical synthesis , Azabicyclo Compounds/pharmacology , Cognition Disorders/drug therapy , Nicotinic Agonists/chemical synthesis , Nicotinic Agonists/pharmacology , Nootropic Agents/chemical synthesis , Nootropic Agents/pharmacology , Oxazoles/chemical synthesis , Oxazoles/pharmacology , Receptors, Nicotinic/chemistry , Schizophrenia/drug therapy , Animals , Azabicyclo Compounds/chemistry , Biological Availability , Cells, Cultured , Epithelial Cells/drug effects , Female , Hippocampus/drug effects , Humans , Kidney/cytology , Kidney/drug effects , Microsomes, Liver/drug effects , Nicotinic Agonists/chemistry , Nootropic Agents/chemistry , Oocytes/drug effects , Oxazoles/chemistry , Rats , Skin/cytology , Skin/drug effects , Structure-Activity Relationship , Xenopus laevis/growth & development , alpha7 Nicotinic Acetylcholine ReceptorABSTRACT
Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist developed as a smoking cessation aid, showed antidepressant-like activity in the forced swim test in two mouse strains. In addition, a low varenicline dose significantly enhanced the effects of moderately active doses of the selective serotonin reuptake inhibitor sertraline. These findings are consistent with the notion that reducing alpha4beta2 nicotinic acetylcholine receptor activity either by antagonists or by partial agonists that can partially activate or desensitize acetylcholine receptors is associated with antidepressant-like properties. These data suggest that varenicline may have antidepressant potential and can, when combined, augment antidepressant responses of selective serotonin reuptake inhibitors.
Subject(s)
Antidepressive Agents/pharmacology , Benzazepines/pharmacology , Depression/drug therapy , Nicotinic Agonists/pharmacology , Quinoxalines/pharmacology , Animals , Antidepressive Agents/administration & dosage , Benzazepines/administration & dosage , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Synergism , Mice , Mice, Inbred C57BL , Mice, Inbred ICR , Nicotinic Agonists/administration & dosage , Quinoxalines/administration & dosage , Receptors, Nicotinic , Selective Serotonin Reuptake Inhibitors/pharmacology , Sertraline/pharmacology , Swimming , VareniclineABSTRACT
The key elimination step for the formation of 3-substituted and 3,6-disubstituted benzynes from 2-haloaryllithiums displays a pronounced solvent-dependent regioselectivity. All 2-haloaryllithiums with electron withdrawing groups in the 6 position are shown by 6Li and 13C NMR spectroscopic studies to be monomers in THF. DFT computational studies implicate trisolvates. Rate studies reveal that LiF eliminates via monomer-based pathways requiring THF dissociation whereas LiCl eliminates via nondissociative pathways. Elimination to form 3-chloro- and 3-fluorobenzyne from 2-chloro-6-fluorophenyllithium displays a pronounced solvent-dependent regioselectivity that is traced to competing solvent-dissociative and nondissociative dissociative pathways for the elimination of LiCl and LiF, respectively.